Document Detail


Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.
MedLine Citation:
PMID:  22843892     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Lapatinib targets human epidermal growth factor-receptor (EGFR) and Her2/neu receptor tyrosine-kinases and hence is under investigation in multimodal therapy concepts of advanced head and neck squamous cell carcinoma (HNSCC). We studied combined effects of lapatinib and cisplatin on colony formation (CF) of epithelial cells of individual HNSCC in short term ex vivo assays.
MATERIALS AND METHODS: Biopsies of HNSCC were minced, collagenase-digested and exposed to serial lapatinib dilutions or solvent control (DMSO). The same lapatinib concentrations were tested in mixture with 1.67 μM, 3.33 or 6.67 μM cisplatin. After α 72-h incubation, adherent cells were ethanol-fixed and epithelial cells were stained using a Cy2™-labeled pan-cytokeratin antibody; then fluorescent colonies were counted.
RESULTS: 33 of 51 ex vivo growing HNSCC (64.7%) exhibited epithelial CF allowing for cut-off detection. Lowest cut-off (complete chemotherapeutical suppressed CF) was noted at 6.25 μM lapatinib in three HNSCC (9.1%). The percentage of HNSCC achieving cut-off by 6.67 μM cisplatin (21.2%) was raised by addition of lapatinib at 6.25, 12.5, and 25 μM up to 33%, 45.5%, and 60.6%, respectively. However, we observed significant inter-individual different dose-response curves of HNSCC in response to lapatinib, e.g. variation in concentrations inhibiting CF to 50% (IC(50)) was 60-fold. At the individual level, antagonism, additivity, and synergism were detected as appropriate models describing the mode of action of cisplatin and lapatinib mixtures.
CONCLUSION: Lapatinib suppresses CF of epithelial HNSCC cells, and in combination with cisplatin its efficacy is increased. However, caution is advisable due to significant heterogeneity in the response of HNSCC to lapatinib alone and when combined with cisplatin.
Authors:
Christoph Schrader; Andreas Boehm; Anett Reiche; Andreas Dietz; Andreas Diet; Christian Mozet; Gunnar Wichmann
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-30     Completed Date:  2012-10-15     Revised Date:  2012-11-20    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3191-9     Citation Subset:  IM    
Affiliation:
Department of Otolaryngology, Head and Neck Surgery, University Hospital Leipzig, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*,  pathology
Cisplatin / administration & dosage,  therapeutic use*
Head and Neck Neoplasms / drug therapy*,  pathology
Humans
Inhibitory Concentration 50
Quinazolines / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
0/Quinazolines; 0VUA21238F/lapatinib; 15663-27-1/Cisplatin
Comments/Corrections
Erratum In:
Anticancer Res. 2012 Sep;32(9):4169
Note: Diet, Andreas [corrected to Dietz, Andreas]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction of DNA damage by curcumin and celecoxib in epithelial cell cultures of the oropharynx afte...
Next Document:  Overexpression of Epstein-Barr Virus-encoded microRNA-BART7 in Undifferentiated Nasopharyngeal Carci...